Kura Oncology has dosed the first subject in the Phase I/II KURRENT clinical trial of its oral experimental drug candidate, tipifarnib, plus alpelisib in HRAS-dependent and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC) patients.
Tipifarnib is an orally bioavailable farnesyl transferase inhibitor while Novartis
